Napp Pharmaceuticals found to breach MHRA advertising guidelines
December 21st, 2007 Posted by: Dr. Cox
The Medicines and Healthcare products Regulatory Agency (MHRA) has found that Napp Pharmaceuticals broke its advertising rules. A complaint was lodged about the firm’s advert for the painkiller BuTrans (buprenorphine matrix patch) in the British Medical Journal in November 2005.
The MHRA upheld a complaint from a healthcare professional that prescribing information was too small to read. Napp admitted the error and agreed to change future adverts.
MHRA Senior Policy Manager Jeremy Mean said: “Pharmaceutical companies are responsible for all aspects of their advertising and its presentation and must ensure that they adhere to strict procedures to ensure the law is upheld. “The work of the MHRA enforces high standards of advertising for medicines to ensure their safe use.”
In a second case it was found promotional literature from the firm Deproco (UK) stated maximum dosages for a range of anaesthetics solutions exceeded the maximum dosage stated in the summary of product characteristics agreed by the MHRA.
© Adfero Ltd
Disclaimer
AllAboutMedicalSales excludes any warranty, express or implied, as to the quality, accuracy, timeliness, completeness or fitness for a particular purpose of this briefing. AllAboutMedicalSales will not be liable for any claims, penalties, losses, damages, costs, or expenses arising from the use of or inability to use this briefing or from any unauthorised access to or alteration of the Briefing. AllAboutMedicalSales makes no warranty that the contents of this briefing are compatible with all computer systems and browsers.